Faculty Appointments
Patient Care Setting
Cancer
Biography
I am a clinician and researcher specializing in the care of patients with both Non Hodgkin and Hodgkin lymphomas. Areas of particular interest include aggressive B-cell lymphomas such as diffuse large B-cell lymphoma and "double hit" lymphoma, autologous stem cell transplantation and cellular therapy including chimeric antigen receptor (CAR) T-cells.
Lymphomas are a complex group of diseases and require a multidisciplinary team to manage. We are fortunate to have an excellent team at the Wilmot Cancer Institute including hematology and oncology, radiation oncology, hematopathology, dermatology, neurology, nursing, advanced practice providers, social work and members of the clinical trials office.
I am actively engaged in clinical trials research and feel that this is an important component of care for lymphoma patients.
My lymphoma practice team includes Taylor Fox, NP and Abir Hines, RN. My team for autologous stem cell transplantation and CAR T-cells includes Anna Morrison, RN.
Professional Background
Dr. Reagan is an Assistant Professor of Medicine at the Wilmot Cancer Institute.
Dr. Reagan received his medical degree from Upstate Medical University in Syracuse, NY. He completed his internship and residency at the University of Virginia. He then served as a chief resident at the University of Virginia. He completed his fellowship in hematology at the Wilmot Cancer Institute at the University of Rochester Medical Center.
He started his faculty appointment at the Wilmot Cancer Institute in July 2015.
Credentials
Specialties
- Hematology - American Board of Internal Medicine
- Internal Medicine - American Board of Internal Medicine
Education
2009
MD | Suny Upstate Medical University
Post-doctoral Training & Residency
07/01/2013 - 06/30/2015
Fellowship in Hematology/Oncology at University of Rochester Medical Center
07/01/2012 - 07/01/2013
Residency in Internal Medicine at University of Virginia Children's Hospital
07/01/2010 - 07/01/2012
Residency in Internal Medicine at University of Virginia Children's Hospital
07/01/2009 - 7/1/2010
Internship in Internal Medicine at University of Virginia Children's Hospital
VIEW ALL expand_more
Awards
2018
Lymphoma Research Foundation Clinical Research Mentoring Program
2015
American Society of Hematology Clinical Research Training Institute
2014
John and Carol Bennett Travel Fellowship Award
Sponsor: John and Carol Bennett
Location: Wilmot Cancer Institute
2009
Alpha Omega Alpha, Upstate Medical University
Sponsor: Upstate Medical University
2005
Phi Beta Kappa, St. Lawrence University
Sponsor: St. Lawrence University
2004
Academic All American, Football, St. Lawrence University
Sponsor: St. Lawrence University
Beta Beta Beta, Biological Honor Society, St. Lawrence University
Sponsor: St. Lawrence University
VIEW ALL expand_more
Clinical Trials
ILYM-15080, KTE-C19-102: A Phase 2 Multicenter Study Evaluating the Efficacy of KTE C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (MCL) (ZUMA-2)
Lead Researcher: Patrick M Reagan
The primary objective of the study is to evaluate the efficacy of brexucabtagene autoleucel (KTE-X19) in participants with relapsed/refractory mantle cell lymphoma (MCL)
View Study Details
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade
Lead Researcher: Patrick M Reagan
The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
View Study Details
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients (EA4181)
Lead Researcher: Patrick M Reagan
This phase II trial compares three chemotherapy regimens consisting of bendamustine, rituximab, high dose cytarabine, and acalabrutinib and studies how well they work in treating patients with newly diagnosed mantle cell lymphoma. Drugs used in chemotherapy, such as bendamustine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This study is being done to find out if one the drug combinations of bendamustine, rituximab, high dose cytarabine, and acalabrutinib is better or worse than the usual approach for mantle cell lymphoma.
View Study Details
Publications
Journal Articles
9/3/2021
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan P, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Crump M, Kuruvilla J, Van Den Neste EW, Farooq U, Navale L, DePuy V, Kim JJ, Gisselbrecht C. "Comparison of 2-year outcomes with CAR T cells (ZUMA-1) versus salvage chemotherapy in refractory large B-cell lymphoma." Blood advances.. 2021 Sep 3; Epub 2021 Sep 03.
7/13/2021
Janelsins MC, Mohamed M, Peppone LJ, Magnuson A, Belcher EK, Melnik M, Dakhil S, Geer J, Kamen C, Minasian L, Reagan PM, Mohile SG, Morrow GR, Ahles TA, Heckler CE. "Longitudinal Changes in Cognitive Function in a Nationwide Cohort Study of Patients with Lymphoma Treated with Chemotherapy." Journal of the National Cancer Institute.. 2021 Jul 13; Epub 2021 Jul 13.
3/30/2021
Wallace D, Reagan PM. "Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells." Drugs.. 2021 Mar 30; Epub 2021 Mar 30.
VIEW ALL PUBLICATIONS